LCCC1841: A Phase 2 Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if acalabrutinib is effective in treating a type of
cancer call central nervous system (CNS) lymphoma. Acalabrutinib has not been approved by the
Food and Drug Administration (FDA) for the treatment of CNS lymphoma. However, FDA has
approved its use for treatment of another type of lymphoma called mantle cell lymphoma.
Currently, there are no standard FDA approved treatments for treatment of CNS lymphoma.
Acalabrutinib acts similar to another cancer drug called ibrutinib. Ibrutinib was tested in
several research trials for management of CNS lymphomas, and the results were promising.
Acalabrutinib and ibrutinib attack a similar target found in CNC lymphoma. Research studies
show that acalabrutinib does a better job in attacking this target than ibrutinib, and this
might be beneficial for using this drug in treating CNS lymphoma. The purpose of this study
is test whether giving acalabrutinib is safe and could help controlling with CNS lymphoma.
The study doctors will be looking to see if acalabrutinib can shrink the cancer.
In this research study, participants will be given acalabrutinib and isavuconazol, because it
helps in preventing fungal infections. Fungal infection is a common side effect of
acalabrutinib. Treatment with acalabrutinib and isavuconazole will continue unless the cancer
progresses or participants experience bad side effects.